Form 8-K Dare Bioscience, Inc. For: Jul 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Dare Bioscience faces Nasdaq delisting over equity deficiency
July 17, 2026 4:10 PM EDTDare Biosciences, Inc. (NASDAQ: DARE) received a notification from Nasdaq's Listing Qualifications Staff on July 13, 2026, stating that the company no longer complies with Nasdaq Listing Rule 5550(b).
According to the company's Form 10-Q for the period ended March 31, 2026, stockholders' equity fell below the required... More
